Reference measurement procedures for Alzheimer’s disease cerebrospinal fluid biomarkers: definitions and approaches with focus on amyloid β42

High Education May Offer Protection Against Tauopathy in Patients with Mild Cognitive Impairment

(2017) Sindre Rolstad et al.   JOURNAL OF ALZHEIMERS DISEASE

Association Study of Clusterin Polymorphism rs11136000 With Late Onset Alzheimer’s Disease in Chinese Han Population

(2012) Jian-Fang Ma et al.   American Journal of Alzheimers Disease and Other Dementias

Cerebrospinal Fluid Levels ofβ-Amyloid 1-42, but Not of Tau, Are Fully Changed Already 5 to 10 Years Before the Onset of Alzheimer Dementia

(2012) Peder Buchhave   ARCHIVES OF GENERAL PSYCHIATRY

Analytical aspects of molecular Alzheimer’s disease biomarkers

(2012) Ulf Andreasson et al.   Biomarkers in Medicine

Novel AβIsoforms in Alzheimer's Disease - Their Role in Diagnosis and Treatment

(2012) Erik Portelius et al.   CURRENT PHARMACEUTICAL DESIGN

Age and diagnostic performance of Alzheimer disease CSF biomarkers

(2012) N. Mattsson et al.   NEUROLOGY

The Alzheimer’s Association external quality control program for cerebrospinal fluid biomarkers

(2011) Niklas Mattsson et al.   Alzheimers & Dementia

The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease

(2011) Guy M. McKhann et al.   Alzheimers & Dementia

The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease

(2011) Marilyn S. Albert et al.   Alzheimers & Dementia

Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: A consensus paper from the Alzheimer's Biomarkers Standardization Initiative

(2011) Hugo Vanderstichele et al.   Alzheimers & Dementia

Quantitation of amyloid beta peptides Aβ1–38, Aβ1–40, and Aβ1–42 in human cerebrospinal fluid by ultra-performance liquid chromatography–tandem mass spectrometry

(2011) Mary E. Lame et al.   ANALYTICAL BIOCHEMISTRY

LC–MS/MS for protein and peptide quantification in clinical chemistry

(2011) Manfred Rauh   JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES

Characterization of the New Serum Protein Reference Material ERM-DA470k/IFCC: Value Assignment by Immunoassay

(2010) I. Zegers et al.   CLINICAL CHEMISTRY

Inter-laboratory variation in cerebrospinal fluid biomarkers for Alzheimer's disease: united we stand, divided we fall

(2010) Niklas Mattsson et al.   CLINICAL CHEMISTRY AND LABORATORY MEDICINE

Traceability of values for catalytic activity concentration of enzymes: a Certified Reference Material for aspartate transaminase

(2010) Brigitte Toussaint et al.   CLINICAL CHEMISTRY AND LABORATORY MEDICINE

Standardization in clinical enzymology: a challenge for the theory of metrological traceability

(2010) Ilenia Infusino et al.   CLINICAL CHEMISTRY AND LABORATORY MEDICINE

Standardizing plasma protein measurements worldwide: a challenging enterprise

(2010) Giampaolo Merlini et al.   CLINICAL CHEMISTRY AND LABORATORY MEDICINE

Revising the definition of Alzheimer's disease: a new lexicon

(2010) Bruno Dubois et al.   LANCET NEUROLOGY

Cerebrospinal fluid and plasma biomarkers in Alzheimer disease

(2010) Kaj Blennow et al.   Nature Reviews Neurology

Reference Measurement Procedure Development for C-Reactive Protein in Human Serum

(2009) Eric L. Kilpatrick et al.   ANALYTICAL CHEMISTRY

Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects

(2009) Leslie M. Shaw et al.   ANNALS OF NEUROLOGY

Traceability as a unique tool to improve standardization in laboratory medicine

(2009) Mauro Panteghini   CLINICAL BIOCHEMISTRY

CSF Biomarkers and Incipient Alzheimer Disease in Patients With Mild Cognitive Impairment

(2009) Niklas Mattsson   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study

(2009) Pieter Jelle Visser et al.   LANCET NEUROLOGY

Multi-site assessment of the precision and reproducibility of multiple reaction monitoring–based measurements of proteins in plasma

(2009) Terri A Addona et al.   NATURE BIOTECHNOLOGY

A worldwide multicentre comparison of assays for cerebrospinal fluid biomarkers in Alzheimer's disease

(2009) N A Verwey et al.   ANNALS OF CLINICAL BIOCHEMISTRY

Toward Système International d’Unité-traceable protein quantification: From amino acids to proteins

(2008) William I. Burkitt et al.   ANALYTICAL BIOCHEMISTRY

The IFCC Reference Measurement System for HbA1c: A 6-Year Progress Report

(2008) C. Weykamp et al.   CLINICAL CHEMISTRY

Characterization of Tau in Cerebrospinal Fluid Using Mass Spectrometry

(2008) Erik Portelius et al.   JOURNAL OF PROTEOME RESEARCH

Solid-phase extraction enhances detection of beta-amyloid peptides in plasma and enables Aβ quantification following passive immunization with Aβ antibodies

(2007) Thomas A. Lanz et al.   JOURNAL OF NEUROSCIENCE METHODS